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A diagnostic method has been developed to detect anti-Leishmania donovani immunoglobulin G (IgG) in
urine by enzyme-linked immunosorbent assay (ELISA). In measuring anti-L. donovani IgG, IgA, and IgM in
urine, the method performed best in the detection of IgG. The sensitivity and specificity of the assay were
determined with panels of urine samples from 62 visceral leishmaniasis (VL) patients, 59 healthy controls from
areas of endemicity, 53 healthy controls from areas of nonendemicity, 59 malaria patients, 13 tuberculosis
patients, 23 cutaneous leishmaniasis patients, and 7 patients with other diseases. Using L. donovani promas-
tigote crude antigen, the test had 93.5% sensitivity (58 positives of 62 VL patient samples) and 89.3% specificity
(191 negatives of 214 non-VL patient samples). The ELISA with acetone-treated L. donovani promastigote
antigen raised the sensitivity and specificity to 95.0 and 95.3%, respectively. Western blot analysis revealed that
most of the samples that cross-reacted with crude antigen in ELISA did not recognize any antigenic component
of L. donovani crude antigen. We also checked 40 serum samples from the same group of VL patients for anti-L.
donovani IgG and got 90.0% sensitivity with both crude and acetone-treated antigens. As collection of urine is
much easier than collection of serum, the detection of anti-L. donovani IgG in urine with acetone-treated
antigen will be useful in epidemiological studies. It could be an adjunct of laboratory diagnosis.
Visceral leishmaniasis (VL) is caused by protozoan parasites
of the genus Leishmania and is transmitted by an insect vector,
the phlebotomine sandfly. More than 47 countries are cur-
rently affected by leishmaniasis, with at least 200 million peo-
ple at risk and approximately 100,000 new cases annually (2).
Ninety percent of the cases occur in Bangladesh, India, Nepal,
and Sudan. Bangladesh alone contributes about 15,000 new
cases annually (10). Both the disease incidence and its severi-
ty—it is lethal if left untreated—are linked to poverty: malnu-
trition is associated with 8.7-times-higher risk for VL (7). Since
the disease occurs mainly in areas where health services are
poorly developed, the development of a simple, cheap, and
reliable diagnostic method is necessary.
Demonstration of the parasites in bone marrow aspirates or
needle biopsy specimens of the spleen and lymph node or by
vitro cultivation are the definitive methods of diagnosis (27).
However, these methods are insufficiently sensitive, and the
techniques are invasive, painful, and even hazardous (24). A
number of serological tests have been developed and evaluated
for the diagnosis of VL, including immunofluorescent-antibody
tests (40, 43), enzyme-linked immunosorbent assay (ELISA)
(12, 14, 15, 20, 22, 25, 33, 42, 46), dot ELISA (23, 31, 36),
immunoblot analysis (28, 34, 35), and the direct agglutination
test (DAT) (6, 17, 18, 19, 29, 30, 32, 41). Due to its simplicity
and high sensitivity and specificity, the DAT has already been
introduced as a routine serological test for diagnosis of VL in
India and Bangladesh, and the parameters of the test have
been established under local conditions (1, 8, 9, 10, 13, 41).
In general, urine samples can be collected more easily than
serum samples. To take advantage of this, several immunodi-
agnostic methods using urine have been established for some
other diseases, like filariasis (21) and schistosomiasis (37). Ko-
hanteb et al. (26) reported the detection of soluble antigen and
antibody in the urine of VL patients by double-countercurrent
immunoelectrophoresis, and de Colmenares et al. (11) de-
tected antigenic compounds in urine by the Western blot tech-
nique. More recently, a latex agglutination test for the detec-
tion of Leishmania donovani antigen in urine was reported with
good specificity but with sensitivity similar to that of micro-
scopic diagnosis (3).
In this paper, we report a sensitive and specific ELISA to
detect anti-L. donovani immunoglobulin G (IgG) in urine us-
ing acetone-treated promastigote antigen.
MATERIALS AND METHODS
Urine and serum samples. Sixty-two urine samples from defined VL patients
were collected from different medical college hospitals in Bangladesh. VL was
diagnosed on the basis of clinical symptoms, including intermittent chronic fever
for at least 1 month, hepatosplenomegaly, anemia, and wasting, along with
hematological features of pancytopenia and reversed albumin globulin ratio and
positive response to sodium antimony treatment. Among the 62 patients, 20 were
confirmed parasitologically: Leishman-Donovan bodies were detected in splenic
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aspirates of seven patients and bone marrow aspirates of five patients, and
promastigotes were demonstrated in eight patients after inoculations of aspirate
materials in Novy, MacNeal, and Nicolle medium. Of the other patients, 39 were
DAT positive, and the remaining 3 were aldehyde test positive (DAT was not
done). In Bangladesh, the DAT (13) and the aldehyde test are used as routine
serological tests for VL. During the collection of samples, all patients were in a
course of treatment with sodium antimony gluconate at the World Health Or-
ganization recommended dose of 20 mg/kg of body weight (intramuscular or
intravenous) or a maximum dose of 850 mg/day for 20 days (44). The average age
of the patients was 26 years, ranging from 4 to 65 years. Fifty-nine control
samples were taken from apparently healthy individuals in Bangladesh having no
past history of kala-azar. In selecting healthy controls from areas of endemicity,
we tried to match the age and sex with those of VL patients. Fifty-three samples
from healthy Japanese individuals were used as healthy controls from areas of
nonendemicity. Thirteen tuberculosis samples were collected from the Tubercu-
losis Hospital, Rajshahi, Bangladesh. Seven samples from patients with other
diseases, including two patients with amebic liver abscess, two patients with
aplastic anemia, one patient with aplastic anemia with nephrotic syndrome, one
patient with aortic stenosis, and one patient with viral fever, were collected from
Rajshahi Medical College Hospital, Rajshahi, Bangladesh. Fifty-nine malaria
patient samples collected in the Solomon Islands and 23 cutaneous leishmaniasis
(CL) patient samples from Ecuador were also used. Immediately after collection,
NaN3 was added to each sample at a final concentration of 0.1% as a preservative
to prevent bacterial growth. The samples were stored at 4°C except during the
period of transportation to Japan. After the collection of urine, the samples were
tested for antibodies within 12 months. In another study, it was shown that the
filaria-specific IgG4 titer in urine samples preserved with 0.1% NaN3 and stored
at 4°C did not change within 1 year (unpublished data). Also, filaria-specific IgG4
units in urine samples preserved with 0.1% NaN3 and stored at 37°C did not
change within 4 weeks (21).
Forty serum samples from the same group of VL patients and 54 Japanese
control sera, obtained from different individuals in the healthy control group
from areas of nonendemicity for urine samples, were used in this study.
The participants were first informed that these samples would be carried to
Japan for research purposes only and not for the diagnosis of their individual
disease. Then, all the samples were collected with consent from the patients or
from their parents when they were of minor age.
Parasite and antigen. L. donovani strain DD8, isolated from a Bangladeshi
patient, was used (38). Promastigotes were maintained in blood agar medium
(USMARU; Difco) containing 20% defibrinated rabbit blood (Nippon Bio-Test
Laboratories Inc., Tokyo, Japan) at 25°C (39). Mass cultivation of parasites was
done in RPMI 1640 medium containing L-glutamine and NaHCO3 (Sigma, St.
Louis, Mo.) supplemented with 100 U of penicillin G/ml, 50 g of streptomycin/
ml, and 1 mg of L-proline/ml. The parasites were harvested when a majority of
the population of promastigotes attained elongated shape; they were washed
three times with phosphate-buffered saline (PBS), pH 7.4, at 4°C by centrifuga-
tion at 1,600  g for 15 min each time. The final pellets were kept at 40°C until
they were used.
(i) Crude antigen. The pellets were resuspended in 20 volumes of cold (4°C)
PBS containing protease inhibitor cocktail (Sigma) followed by sonication in an
ice bath. The lysate was centrifuged at 15,000  g for 15 min at 4°C. The
supernatant was collected, and the protein concentration was measured by pro-
tein assay (Bio-Rad, Richmond, Calif.) (1 g of protein/1.3 105 promastigotes)
and stored at 40°C.
(ii) Acetone-treated antigen. The pellets were resuspended in 20 volumes of
cold acetone, incubated at 20°C for 2 h, and then centrifuged at 15,000  g for
10 min at 10°C. The supernatant was discarded, and the sediment was dried by
gentle suctioning. The sediment was resuspended in 20 volumes of cold PBS
(4°C) containing protease inhibitors, followed by sonication, centrifugation, and
estimation of the protein concentration (1 g of protein/4.2  105 promastig-
otes) as described for the crude antigen, and finally stored at 40°C.
ELISA. ELISA was carried out in flat-bottom 96-well microtiter plates (Maxi-
Sorp; Nunc, Roskilde, Denmark). The plates were coated with 5 g of crude or
acetone-treated antigen/ml (100 l/well) in coating buffer (0.05 M carbonate-
bicarbonate buffer, pH 9.6) and incubated overnight at 4°C. After being blocked
with casein buffer (1% casein in 0.05 M Tris-HCl buffer with 0.15 M NaCl, pH
7.6) for 2 h at room temperature, the wells were loaded with 100 l of urine (1:10
dilution in casein buffer) or serum (1:4,000 dilution in casein buffer) and incu-
bated at 37°C for 1 h. The plates were washed four times with PBS containing
0.05% Tween 20 (pH 7.4) and incubated with peroxidase-conjugated goat anti-
human IgG (Tago, Camarillo, Calif.), IgA (Zymed, South San Francisco, Calif.),
or IgM (Tago) (1:4,000 dilution in casein buffer) at 37°C for 1 h. After being
washed four times, the plates were incubated with substrate ABTS (KPL Inc.,
Gaithersburg, Md.) for 1 h at room temperature, and the optical density was
measured at 415 nm. Each sample was assayed in duplicate.
Antibody levels were expressed as units on the basis of a standard curve. To
construct the curve, pooled sera from four VL patients were serially diluted
threefold (1:20,000 to 1:14,580,000) with casein buffer supplemented with sodium
azide, and a set of the serially diluted sera was prepared for each microtiter plate.
As antibody units, a value of 7,290 U was arbitrarily assigned to the 1:20,000
dilution and a value of 10 U to the 1:14,580,000 dilution. Antibody unit levels of
7,290 U were considered as 7,290 U. The cutoff point for anti-L. donovani IgG
was set as the mean plus 3 standard deviations of log (unit  1) values of the
healthy controls from areas of nonendemicity and of the Japanese controls for
urine and serum, respectively, to obtain maximum sensitivity and specificity.
With crude antigen, the antilogarithmic cutoff values for urine and serum were
8.2 and 443.0 U, respectively. With acetone-treated antigen, the antilogarithmic
values were 7.4 U for urine and 313.9 U for serum. The cutoff points for anti-L.
donovani IgA and IgM were set as the means plus 3 standard deviations of log
(optical density  1) values of the healthy controls from areas of nonendemicity,
and the antilogarithmic values were 0.045 for IgA and 0.008 for IgM.
Immunoblot analysis. Crude antigen samples were electrophoresed on sodium
dodecyl sulfate–8 to 16% polyacrylamide gels, 1.5 mm thick (Tefco, Tokyo,
Japan), with a wide-range molecular mass marker (Tefco). The separated pro-
teins were transferred to polyvinylidene difluoride membranes (0.45-m pore
size) under constant voltage at 100 V for 1.5 h in a transblotting chamber
(Bio-Rad). The membrane was blocked for 20 min with casein buffer and incu-
bated with two-times-diluted urine at 37°C for 1 h. After three washes with casein
buffer, the membrane strips were incubated with peroxidase-conjugated goat
anti-human IgG (1:1,000 dilution) for 1 h at 37°C. Bound antibodies were
visualized with Konica immunostaining HRP-100 (Seikagaku Corp., Tokyo, Ja-
pan). The relative molecular weights of the detected bands were calculated with
Quantity One software (version 2.7; PDI, Inc., New York, N.Y.).
RESULTS
Anti-L. donovani IgG. Urine samples from 62 VL and 214
non-VL patients were tested for IgG, using crude antigen (Fig.
1a). The test showed a sensitivity of 93.5% (58 positives of 62
VL patient samples) and a specificity of 89.3% (191 negatives
of 214 non-VL patient samples). Urine samples from 60 VL
and 214 non-VL patients were tested for IgG, using acetone-
treated antigen (Fig. 1b). Two VL patient samples could not be
tested because of inadequate quantity. The test showed in-
creased sensitivity and specificity compared to the crude anti-
gen, with a sensitivity of 95.0% (57 positives of 60 VL patient
samples) and a specificity of 95.3% (204 negatives of 214
non-VL patient samples). In both assays, the healthy controls
from areas of endemicity and nonendemicity showed 100%
specificity. In the other-diseases category, two false positives—
aplastic anemia and aplastic anemia with nephrotic syn-
drome—were detected in both assays. The specificities for ma-
laria, tuberculosis, and CL were improved in the assay with
acetone-treated antigen (Table 1).
Serum samples from 40 VL patients and 54 Japanese con-
trols were tested for IgG using both crude and acetone-treated
antigens (Fig. 2). Both assays showed the same sensitivity and
specificity, which were 90.0 and 100%, respectively (Table 1).
Anti-L. donovani IgA and IgM. Urine samples from 45 VL
and 34 non-VL patients were tested for IgA and IgM with
crude antigen (Table 1). Both assays showed poor sensitivities,
37.8% for IgA and 66.7% for IgM. Samples from four patients
with other diseases (one patient with amebic liver abscess, two
patients with aplastic anemia, and one patient with aplastic
anemia with nephrotic syndrome) gave false-positive results
with IgA. One healthy control from an area of endemicity and
three patients with other diseases (two patients with aplastic
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anemia and one patient with aplastic anemia with nephrotic
syndrome) gave false-positive results with IgM.
Immunoblot analysis of the urine samples. Urine samples
for immunoblot analysis were selected according to the ELISA
result of an anti-L. donovani IgG assay using crude antigen. All
23 false-positive and 4 false-negative VL patient samples,
along with randomly selected control samples (six positive VL
patient samples and two negative healthy samples from areas
FIG. 1. Detection of anti-L. donovani IgG in urine of visceral leishmaniasis patients, healthy individuals, and controls with various diseases by
ELISA with crude antigen (a) or acetone-treated antigen (b). Each symbol (F) stands for a single urine sample. The horizontal dotted lines
represent the cutoff values: 8.2 (a) and 7.4 (b) U. EHC, healthy controls from areas of endemicity; NEHC, healthy controls from areas of
nonendemicity; M, malaria; TB, tuberculosis; OD, other diseases; n, number of samples.
TABLE 1. Sensitivity and specificity of ELISA for the detection of different immunoglobulin classes in urine and
serum using L. donovani crude antigen or acetone-treated antigen
Sample Antigen Ig class Sensitivityfor VLa
Specificitya,b
EHC NEHC M TB CL OD
Urine Acetone treated IgG 57/60 (95.0) 59/59 (100) 53/53 (100) 54/59 (91.5) 13/13 (100) 20/23 (87.0) 5/7 (71.4)
Crude IgG 58/62 (93.5) 59/59 (100) 53/53 (100) 44/59 (74.6) 12/13 (92.3) 18/23 (78.3) 5/7 (71.4)
IgM 30/45 (66.7) 12/13 (92.3) 14/14 (100)    4/7 (57.1)
IgA 17/45 (37.8) 13/13 (100) 14/14 (100)    3/7 (42.9)
Serum Acetone treated IgG 36/40 (90.0)  54/54 (100)    
Crude IgG 36/40 (90.0)  54/54 (100)    
a Number positive/total (percent).
b EHC, healthy controls from areas of endemicity; NEHC, healthy controls from areas of nonendemicity; M, malaria; TB, tuberculosis; OD, other diseases; , not
tested.
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of endemicity) were tested for IgG reactivity (Fig. 3). All pos-
itive VL patient samples recognized numerous antigenic com-
ponents ranging from 10 to 283 kDa. Antigenic components of
126, 116, 94, 84, 65, 60, 55, 45, 41, and 29 kDa were frequently
recognized by VL patient samples, of which 126 and 116 kDa
were common to all. Only one false-negative VL patient sam-
ple faintly recognized a single band at the 51-kDa position.
This sample proved to be positive with the acetone-treated
antigen in ELISA. The other three false negatives did not
react, but two of them were parasite positive. Two negative
(healthy controls from areas of endemicity) samples and 8 out
of 15 malaria patient samples did not recognize any compo-
nent. Two aplastic anemia patient samples recognized several
antigenic components, of which 60, 45, 41, and 29 kDa were
shared among some of the VL patient samples. The tubercu-
losis patient sample recognized the 132-kDa component. Of
five CL patient samples, one recognized several components,
of which the 65-kDa component was common in some of the
VL patient samples. Another CL patient sample recognized
two components very faintly, and the other three did not rec-
ognize any.
DISCUSSION
Detection of parasites is most definitive in the diagnosis of
VL. However parasitological diagnosis is invasive and often
not sensitive. Zijlstra et al. (45) found sensitivities of 93.1, 67.1,
and 56.3% for the demonstration of causative parasites in
spleen, bone marrow, and lymph node aspirates, respectively,
in a study of 87 hospitalized patients. A community-based
survey in Bangladesh showed that only 29 of 125 (23%) clini-
cally suspected persons were confirmed parasitologically, but
all responded favorably to treatment (8). In another study
conducted in Bangladesh with 715 parasitologically confirmed
and 558 parasitologically negative but clinically confirmed
kala-azar patients, 97.5% responded successfully to sodium
antimony treatment; among them, 90% showed response
within 3 to 5 days of treatment (10). In these situations and
because of the serious therapeutic implications related to an
incorrect or late diagnosis of VL, there is a strong need for an
accurate laboratory test to confirm the clinical diagnosis. Ad-
ditionally, this disease occurs mostly in young populations. A
study in Brazil reported that 78% of cases occurred in children
5 years of age (4). Another study in Bangladesh reported that
a majority (98.2%) of VL patients were below 25 years old
(10). Therefore, the diagnostic method should be easy and
readily acceptable to such populations. Our ELISA with urine
would meet this requirement in terms of relative ease in col-
lecting samples. In this assay system, serum was not a better
sample than urine. The ELISA will be particularly useful in
epidemiological studies.
One of the problems of serological assays for VL is the
existence of cross-reactions with other diseases, including Afri-
can trypanosomiasis (sleeping sickness), mucocutaneous leish-
maniasis, cutaneous leishmaniasis, malaria, tuberculosis, lep-
rosy, and amebiasis, which are coendemic in some parts of the
world (5, 17, 23, 31). In our study, a considerable number of
cross-reactions with malaria, tuberculosis, CL, and aplastic
anemia were noted with the crude antigen. With the use of
acetone-treated antigen, one out of four false-negative VL
patient samples turned to positive and 13 out of 23 false-
positive samples (10 malaria, 1 tuberculosis, and 2 CL patient
samples) turned to negative and improved the total sensitivity
to 95.0% and the specificity to 95.3%. The immunoblot anal-
ysis revealed that most of the samples which proved to be
FIG. 2. Detection of anti-L. donovani IgG in sera of VL patients and healthy Japanese controls by ELISA with crude antigen (a) or acetone-
treated antigen (b). Each symbol (F) stands for a single serum sample. The horizontal dotted lines represent the cutoff values: 443.0 (a) and 313.9
(b). JC, Japanese controls; n, number of samples.
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negative with the acetone-treated antigen did not recognize
any antigenic component, whereas those samples remaining
positive detected several antigenic components. As acetone
treatment caused the removal of lipid from parasite antigens,
cross-reactions due to lipid portions must have been reduced.
Use of the acetone-treated antigen could not reduce cross-
reactions in aplastic anemia. Two of the three aplastic anemia
patient samples showed very high antibody titers with all
classes of immunoglobulins. The patients did not have any
history of VL. As aplastic anemia patients need frequent blood
transfusions, the possibility of receiving blood with a high an-
tibody titer against L. donovani cannot be ruled out. Further
investigations are necessary to distinguish these two, as both
diseases cause pancytopenia.
In a posttreatment follow-up, Hailu (16) reported that the
rate of negative change was 50% up to 1 year and 89% from 2
to 8 years with serum-based ELISA. In contrast, with the DAT
it was 0% by 1 year and only 33% by 2 to 8 years. This indicates
that the performance of ELISA is better than that of the DAT
in the posttreatment follow-up. It will be worthwhile to test our
urine-based ELISA after treatment. In addition, the potential
use of ELISA in early detection of asymptomatic and subclin-
ical infection and the prognosis after early treatment also need
evaluation.
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